Filtered By:
Condition: Overdose
Nutrition: Vitamins

This page shows you your search results in order of date.

Order by Relevance | Date

Total 29 results found since Jan 2013.

Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
Conclusions Our analysis suggests that off-label underdosing of NOACs does not reduce bleeding outcomes. Patients prescribed off-label NOAC doses are at an increased risk of all-cause mortality. These data underscore the importance of prescriber adherence to NOAC dosing guidelines to achieve optimal clinical outcomes for patients with AF. PROSPERO registration number CRD42020219844.
Source: Heart - January 11, 2023 Category: Cardiology Authors: Caso, V., de Groot, J. R., Sanmartin Fernandez, M., Segura, T., Blomström-Lundqvist, C., Hargroves, D., Antoniou, S., Williams, H., Worsley, A., Harris, J., Caleyachetty, A., Vardar, B., Field, P., Ruff, C. T. Tags: Open access Systematic review Source Type: research

Prevalence and risk of inappropriate dosing of direct oral anticoagulants in two Swiss atrial fibrillation registries
CONCLUSION: Inappropriate DOAC-dosing was more prevalent in multimorbid patients, but did not correlate with higher risks of adverse events after adjusting for confounders. DOAC prescription should follow label.PMID:36182083 | DOI:10.1016/j.vph.2022.107120
Source: Vascular Pharmacology - October 1, 2022 Category: Drugs & Pharmacology Authors: Giulia Montrasio Martin F Reiner Andrea Wiencierz Stefanie Aeschbacher Christine Baumgartner Nicolas Rodondi Michael K ühne Giorgio Moschovitis Helga Preiss Michael Coslovsky Maria L De Perna Leo H Bonati David Conen Stefan Osswald Juerg H Beer Pascal Ko Source Type: research

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care
ConclusionsInappropriate NOAC dosing is present in almost twenty percent of AF patients according to the SmPC and requires further education of health care professionals and frequent reassessment of NOAC dosing. However, a significant lower prevalence of underdosing was present when judged by the 2018 EHRA criteria, likely reflecting decision making in complex AF patients. Perceived frailty, weight, renal function and type of NOAC are the main determinants of deviated dosing.
Source: Clinical Drug Investigation - August 20, 2022 Category: Drugs & Pharmacology Source Type: research

Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80  Years and Over
ConclusionsAmong patients with non-valvular atrial fibrillation aged 80 years and over, about 40% of DOAC prescriptions feature inappropriate dose levels. It might be possible to reduce inappropriate dosing by raising awareness among hospital-based and private-practice prescribers, providing prescription support tools for DOACs, and performing medication reconciliations and reviews at hospital and in private practice.
Source: Drugs and Aging - September 6, 2021 Category: Geriatrics Source Type: research

Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation
Circ J. 2021 Jun 5. doi: 10.1253/circj.CJ-21-0399. Online ahead of print.ABSTRACTStroke prevention is the cornerstone of management of atrial fibrillation (AF), and non-vitamin K antagonist oral anticoagulants (NOACs) are commonly prescribed. Because routine monitoring of anticoagulant effects of NOACs is not necessary, appropriate dosing following the criteria of each NOACs defined in pivotal randomized trials is important. Real-world data demonstrate that underdosing NOACs is associated with a higher risk of ischemic stroke without a lower risk of major bleeding. Furthermore, renal function of AF patients should be asses...
Source: Circulation Journal - June 7, 2021 Category: Cardiology Authors: Wen-Han Cheng Yi-Hsin Chan Jo-Nan Liao Ling Kuo Shih-Ann Chen Tze-Fan Chao Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis
ConclusionThe benefit-risk profile of NOACs seems preserved in (morbidly) obese AF patients and patients with low body weight. However, more data are needed on underweight AF patients (BMI<  18.5 kg/m2) and on differences between NOACs in these patients.
Source: Cardiovascular Drugs and Therapy - January 11, 2021 Category: Cardiology Source Type: research

Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation
AbstractOptimal antithrombotic treatment of older patients is usually impeded by several prevailing misconceptions. The aim of our study was to assess the type, dosage and predictors of antithrombotic therapy in older patients with non-valvular atrial fibrillation (NVAF). PAVE-AF was a prospective, cross-sectional study, including NVAF patients ≥ 80 years from 30 participating centers. Demographic data, comorbidities and treatment patterns were documented in a single visit. Patients treated with non-vitamin K oral anticoagulants (NOACs) were further classified into three dosing categories (recommended, underdosing and o...
Source: Journal of Thrombosis and Thrombolysis - June 8, 2020 Category: Hematology Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
CONCLUSIONS: Initiation of apixaban versus NOACs was more common among patients with increased age, higher bleeding risk and decreased renal function, whereas initiation of apixaban versus VKAs was more common among patients with lower bleeding risk and better renal function. PMID: 31014991 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - April 19, 2019 Category: Cardiology Authors: Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG Tags: Arch Cardiovasc Dis Source Type: research

Inappropriate non-vitamin  K antagonist oral anticoagulants prescriptions: be cautious with dose reductions.
CONCLUSION: An incorrect prescription occurred more often in the reduced-dose NOAC group. Clinical parameters such as renal function are often unknown whilst these are essential to determine the right NOAC and dose. PMID: 30949972 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - April 3, 2019 Category: Cardiology Authors: Jacobs MS, van Hulst M, Campmans Z, Tieleman RG Tags: Neth Heart J Source Type: research

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
AbstractThe current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchelet al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace 2013;15:625 –651; Heidbuchelet al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467 –1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in pati...
Source: European Heart Journal - March 19, 2018 Category: Cardiology Source Type: research

Stroke warning: Overdosing on this supplement could cause brain bleeding
SUPPLEMENTS are widely used to boost a healthy diet, and vitamin E is often taken for its antioxidant benefits. However, in excess it can lead to a haemorrhagic stroke.
Source: Daily Express - Health - August 2, 2017 Category: Consumer Health News Source Type: news

Supplement warning: Overdosing on this to lower high blood pressure could be deadly
SUPPLEMENTS popularly used include vitamin C, vitamin D3 and omega-3 - and potassium may also be taken to ward off high blood pressure, heart disease, stroke, arthritis, cancer, digestive disorders, and infertility. However, too much of the mineral could be deadly.
Source: Daily Express - Health - August 1, 2017 Category: Consumer Health News Source Type: news